Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine

Kvirkvelia, Nino, Chikadze, Nino, Makinde, Julia, McBride, Jeffrey D., Porakishvili, Nino, Hills, Frank ORCID: https://orcid.org/0000-0001-8235-7545, Martensen, Pia M., Justesen, Just, Delves, Peter J., Lund, Torben and Roitt, Ivan (2018) Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine. Clinical and Experimental Immunology, 193 (1) . pp. 73-83. ISSN 0009-9104 [Article] (doi:10.1111/cei.13131)

Preview	PDF (Accepted Manuscript text) - Final accepted version (with author's formatting) Download (349kB) | Preview
	PDF (pdf file of submitted manuscript) - Draft pre-submission version (with author's formatting) Restricted to Repository staff and depositor only Download (631kB)

Abstract

Human hCG and its β‐subunit (hCGβ) are tumour autocrine growth factors whose presence in the serum of cancer patients has been linked to poorer prognosis. Previous studies have shown that vaccines, which target these molecules and/or the 37 amino acid C‐terminal hCGβ peptide (hCGβCTP), induce antibody responses in a majority of human recipients. Here we explored whether the immunogenicity of vaccines containing an hCGβ mutant (hCGβR68E, designed to eliminate cross‐reactivity with luteinizing hormone) or hCGβCTP could be enhanced by coupling the immunogen to different carriers (KLH or Hsp70) using different cross‐linkers (EDC or GAD) and formulated with different adjuvants (RIBI or Montanide ISA720).

While there was little to choose between KLH and Hsp70 as carriers, their influence on the effectiveness of a vaccine containing the BAChCGβR68E mutant was less marked, presumably because being a foreign species, this mutant protein itself might provide T‐helper epitopes. The mutant provided a significantly better vaccine than the hCGβCTP peptide irrespective of the carrier used, how it was cross‐linked to the carrier or which adjuvant was used when hCG was the target. Nonetheless, for use in humans where hCG is a tolerated self‐protein, the need for a carrier is of fundamental importance. Highest antibody titres were obtained by linking the BAChCGβR68E to Hsp70 as a carrier by GAD and using RIBI as the adjuvant, which also resulted in antibodies with significantly higher affinity than those elicited by hCGβCTP peptide vaccine. This makes this mutant vaccine a promising candidate for therapeutic studies in hCGβ‐positive cancer patients.

Actions (login required)

View Item

Statistics

DownloadsShow export options

Export as CSVXMLJSON

Activity Overview

6 month trend

243Downloads

6 month trend

342Hits

Additional statistics are available via IRStats2.